Results 121 to 130 of about 39,467 (264)

Expert Perspective: Hematologic Malignancies and Vasculitis

Arthritis &Rheumatology, Volume 77, Issue 10, Page 1305-1316, October 2025.
Michelle L. Robinette, Hetty E. Carraway
wiley   +1 more source

Complications at Diagnosis of Pediatric Chronic Myeloid Leukemia in Chronic Phase

Pediatric Blood &Cancer, Volume 72, Issue 10, October 2025.
ABSTRACT Chronic myeloid leukemia (CML) is uncommon during the first two decades of life, resulting in limited experience of pediatricians in handling this leukemia. This is even more true when it comes to managing rare complications at the time of diagnosis.
Nirmalya Roy Moulik, Uma Athale, Markus Metzler, Frederic Millot, Meinolf Suttorp   +4 more
wiley   +1 more source

Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview. [PDF]

Front Oncol, 2021
Kuendgen A, Kasprzak A, Germing U.
europepmc   +1 more source

Platelet and fibrinogen kinetics in the chronic myeloproliferative disorders [PDF]

, 1972
Isadore Brodsky, S. Benham Kahn, Evelyn M. Ross, Goldie Petkov   +3 more
openalex   +1 more source

Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders. [PDF]

Front Oncol, 2022
Symeonidis A, Chondropoulos S, Verigou E, Lazaris V, Kourakli A, Tsirigotis P.   +5 more
europepmc   +1 more source

The importance of systemic inflammatory response measurements as pretransplant risk factors for outcome after allogeneic haematopoietic cell transplantation

British Journal of Haematology, Volume 207, Issue 4, Page 1517-1528, October 2025.
In oncological patients SIR measures like the mGPS have great impact on prognosis at starting therapy. We recorded at admission for allo‐HCT the mGPS in 2201 patients: score 0 CRP/sALB normal; score 1 CRP >10mg/dl; score 2 CRP >10mg/dl + sALB <35g/L. Multivariate analysis revealed a significant impact with a low GPS score for OS: mGPS 1 vs.
Hartmut Bertz, Jörg Sahlmann, Donald C. McMillan, Claudia Wehr, Jesus Duque‐Afonso, Kristina Maas‐Bauer, Ralph Wäsch, Julia Nikolaychuk, Christine Greil, Jann Arends, Jürgen Finke, Robert Zeiser   +11 more
wiley   +1 more source

Histamine and Serotonin Levels in Bone Marrow Stem Cells Niche as Potential Biomarkers of Systemic Mastocytosis and Myeloproliferative Disorders. [PDF]

Stem Cell Rev Rep, 2023
Janus T, Korbal U, Żukowski M, Lewosiuk A, Koper K, Żukowska A, Brzeźniakiewicz-Janus K.   +6 more
europepmc   +1 more source

Co‐operative epigenetic remodelling by Setd2 deficiency and Kras mutation drives juvenile myelomonocytic leukaemia development and MEK inhibitor sensitivity

British Journal of Haematology, Volume 207, Issue 4, Page 1289-1300, October 2025.
A proposed model of Setd2 deficiency and KrasG12D/+ mutation synergism in the pathogenesis of juvenile myelomonocytic leukaemia (JMML). KrasG12D/+ mutation instigates constitutive activation of the RAS‐ERK1/2 signalling pathway, and Setd2 ablation in the KrasG12D/+ mutant background further hyperactivates the RAS‐ERK1/2 signalling pathway, leading to ...
Gustave Munyurangabo, Linlin Zhang, Ying Zhou, Peihua Zhang, Xiao Yu, Dou Qu, Dan Yang, Xiaomin Ren, Hongwei Liu, Yonghong Wu, Guangyao Kong, Yi Yang   +11 more
wiley   +1 more source

Clonal Myeloproliferative Disorders in Patients with Down Syndrome-Treatment and Outcome Results from an Institution in Argentina. [PDF]

Cancers (Basel), 2022
Pennella CL, Cassina TM, Rossi JG, Baialardo EM, Rubio P, Deu MA, Peruzzo L, Guitter MR, Sanchez de La Rosa CG, Alfaro EM, Felice MS.   +10 more
europepmc   +1 more source

Feasibility and acceptability of an online psychological group intervention for allogeneic hematopoietic stem cell transplantation inpatients

HemaSphere, Volume 9, Issue 10, October 2025.
Karl Haller, Asita Behzadi, Johannes C. Ehrenthal, Lars Bullinger, Johann Ahn   +4 more
wiley   +1 more source